Woodmont Investment Counsel LLC Sells 69 Shares of Zoetis Inc. $ZTS

Woodmont Investment Counsel LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,416 shares of the company’s stock after selling 69 shares during the period. Woodmont Investment Counsel LLC’s holdings in Zoetis were worth $221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ZTS. Vanguard Group Inc. increased its position in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC increased its position in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp raised its stake in Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. grew its position in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after purchasing an additional 312,746 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $145.39 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a fifty day moving average of $149.68 and a 200-day moving average of $154.90. The firm has a market capitalization of $64.43 billion, a P/E ratio of 25.02, a P/E/G ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same period last year, the company posted $1.56 earnings per share. The business’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZTS. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.